migalastat has been researched along with Obesity in 1 studies
*Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY). [MeSH]
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aerts, JM; Bijl, N; Boot, RG; Copeland, D; Ghauharali, K; Groen, AK; Groener, JE; Liu, H; Meijer, AJ; O'Shea, TJ; Ottenhoff, R; Overkleeft, HS; Song, H; van den Berg, RJ; van der Marel, GA; van Eijk, M; Wennekes, T; Yew, N | 1 |
1 other study(ies) available for migalastat and Obesity
| Article | Year |
|---|---|
Dual-action lipophilic iminosugar improves glycemic control in obese rodents by reduction of visceral glycosphingolipids and buffering of carbohydrate assimilation.
Topics: Absorption; Animals; Blood Glucose; Carbohydrate Metabolism; Glycated Hemoglobin; Glycosphingolipids; Imino Sugars; Mice; Mice, Obese; Obesity; Rats; Rats, Zucker; Structure-Activity Relationship; Viscera | 2010 |